AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $225.00, giving the company a market capitalization of 403.47B. It carries a P/E multiple of 170.26 and pays a dividend yield of 2.9%.
As of 2026-02-04, AbbVie(ABBV) stock has fluctuated between $223.64 and $228.70. The current price stands at $225.00, placing the stock +0.6% above today's low and -1.6% off the high.
The AbbVie(ABBV)'s current trading volume is 8.16M, compared to an average daily volume of 6.77M.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
ABBV News
(RTTNews) - AbbVie (ABBV) on Tuesday said it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeki...
AbbVie (ABBV) has submitted applications for a new indication to the FDA and European Medicines Agency, or EMA, for upadacitinib for the treatment of adult and...
Simcere Pharmaceutical Group Limited ( (HK:2096) ) just unveiled an announcement. Simcere Pharmaceutical Group Limited has received a further US$40 million mil...
Analyst ratings
63%
of 32 ratingsMore ABBV News
In recent days, AbbVie has highlighted its shift away from Humira toward newer immunology drugs such as Skyrizi and Rinvoq, while progressing a broad pipeline t...
A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier. In some ways, AbbVie (ABBV +1.17%) isn't the same company it was five years ago. Su...
AbbVie (ABBV) is back in focus after its latest results showed immunology therapies like Skyrizi and Rinvoq offset the hit from Humira's patent expiration, push...
AbbVie entered a voluntary agreement with the Trump administration to invest $100 billion in U.S. research and manufacturing over the next decade and to expand...
Key Points AbbVie is a well-established drugmaker with fast-growing immunology products and a solid dividend program. Abivax could challenge pharmaceutical gi...
West Pharmaceutical Services recently announced a definitive agreement to sell all manufacturing and supply rights for its SmartDose® 3.5mL On-Body Delivery Sys...
On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes AbbVie Inc. (NYSE:ABBV) a...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.